Early Mortality of Brain Infarction Patients and Red Blood Cell Distribution Width

Leonardo Lorente 1,*, Maria M. Martín 2, Pedro Abreu-González 3#, Antonia Pérez-Cejas 4, Agustín F. González-Rivero 4, Luis Ramos-Gómez 5#, Mónica Argueso 6, Jordi Solé-Violán 7, Juan J. Cáceres 8, Alejandro Jiménez 9 and Víctor García-Marin 10

1 Intensive Care Unit, Hospital Universitario de Canarias, Ofra s/n, La Laguna, 38320 Santa Cruz de Tenerife, Spain
2 Intensive Care Unit, Hospital Universitario Nuestra Señora de Candelaria, Crta del Rosario s/n, 38010 Santa Cruz de Tenerife, Spain; mar.martinvelasco@gmail.com
3 Department of Physiology, Faculty of Medicine, University of the La Laguna, Ofra s/n, La Laguna, 38320 Santa Cruz de Tenerife, Spain; pabreu@ull.es
4 Laboratory Department, Hospital Universitario de Canarias, Ofra, s/n, La Laguna, 38320 Santa Cruz de Tenerife, Spain; aperezcejas@gmail.com (A.P.-C.); agonriv@hotmail.com (A.F.G.-R.)
5 Intensive Care Unit, Hospital General La Palma, Buenavista de Arriba s/n, Breña Alta, La Palma, 38713 Santa Cruz de Tenerife, Spain; lramosgomez@gmail.com
6 Intensive Care Unit, Hospital Clínico Universitario de Valencia, Avda, Blasco Ibáñez nº17-19, 46004 Valencia, Spain; moni_begasa@hotmail.com
7 Intensive Care Unit, Hospital Universitario Dr. Negrín, CIBERES, Barranco de la Ballena s/n, 35010 Las Palmas de Gran Canaria, Spain; jsolvio@gobiernodecanarias.org
8 Intensive Care Unit, Hospital Insular, Plaza Dr. Pasteur s/n, 35016 Las Palmas de Gran Canaria, Spain; juanjose.caceresagraw@gobiernodecanarias.org
9 Research Unit, Hospital Universitario de Canarias, Ofra s/n, La Laguna, 38320 Santa Cruz de Tenerife, Spain; ajimenezsosa@gmail.com
10 Department of Neurosurgery, Hospital Universitario de Canarias, Ofra, s/n, La Laguna, 38320 Santa Cruz de Tenerife, Spain; vicgarmar666@gmail.com

* Correspondence: lorentemartin@msn.com

Received: 6 March 2020; Accepted: 24 March 2020; Published: 26 March 2020

Abstract: Background: Meta-analysis has found that high baseline red blood cell distribution width (RDW) is associated with increased long-term mortality (mortality at one year or more) in ischemic stroke. The objectives of this study were to determine whether there is an association between RDW and 30-day mortality, and to explore whether RDW during the first week of ischemic stroke could be a 30-day mortality biomarker. Methods: We included patients with malignant middle cerebral artery infarction (MMCAI). RDW at days 1, 4, and 8 of MMCAI were determined. The end-point study was 30-day mortality. Results: We found that survivor (n = 37) in respect to non-survivor patients (n = 37) had lower RDW at days 1 (p < 0.001), 4 (p < 0.001), and 8 (p = 0.02). The area under curve (95% CI) for prediction of 30-day mortality by RDW at days 1, 4, and 8 of MMCAI were 0.80 (0.69–0.89; p < 0.001), 0.79 (0.66–0.89; p < 0.001), and 0.73 (0.58–0.84; p = 0.02). Regression analysis showed an association between RDW (odds ratio = 1.695; 95% CI = 1.230–2.335; p < 0.001) and 30-day mortality. Conclusions: The association between RDW and early mortality, and the potential role of RDW during the first week of MMCAI as a prognostic biomarker of early mortality were the main novelties of our study.

Keywords: red blood cell distribution width; brain infarction; patients; mortality; prognosis
1. Introduction

Red blood cell distribution width (RDW) represents the variability of form and size in red blood cells of a subject and is a hemogram index that is used for the differential diagnosis of anemia [1]. High RDW has been associated with increased mortality in patients with coronary disease [2], cardiac arrest [3], heart failure [4], pancreatitis [5], liver disease [6], sepsis [7,8], or traumatic brain injury [9].

RDW has been previously scarcely explored in patients with ischemic stroke [10–14]. In a recently published meta-analysis, it has been found that high baseline RDW is associated with increased mortality in ischemic stroke, over all long-term mortality (mortality at one year or more) [10]. In some studies included in the meta-analysis, the end-point was long-term mortality (mortality at one year or more); in two studies it was in-hospital mortality (but the day of death was not reported) [11,12], in one study it was 90-day mortality [13], and in one study it was 30-day mortality [14]. However, in the study by Duchnowsi et al. the aim was to evaluate the prognostic value of RDW for ischemic stroke in the early postoperative period in patients undergoing valve replacement. Only 14 patients developed perioperative ischemic stroke, and only 4 patients were dead at 30 days; therefore, is difficult to establish the role of RDW for 30-day mortality prediction in ischemic stroke [14]. Thus, there is not conclusive data on the role of RDW for early mortality prediction in ischemic stroke, and the objectives of this study were to compare RDW during the first week of brain infarction in 30-day surviving and non-surviving patients, to determine whether there is an association between RDW and 30-day mortality, and to explore whether RDW during the first week of brain infarction could be a 30-day mortality biomarker.

2. Methods

2.1. Design and Subjects

This prospective and observational study was performed in six Spanish hospitals with the approval of the Institutional Board of each hospital (CHUC-2009-46): H. General de La Palma, H. Universitario Dr. Negrín (Gran Canaria), H. Universitario Nuestra Señora de Candelaria (Tenerife), H. Insular (Gran Canaria), H. Clínico Universitario de Valencia, and H. Universitario de Canarias (Tenerife). Additionally, the inclusion of patients was performed with the written and signed consent of a relative of each patient.

Patients with malignant middle cerebral artery infarction (MMCAI) were included. We established the diagnosis of MMCAI with the presence of an acute middle cerebral artery infarction with parenchymal hypodensity in at least of 50% of this territory and midline shift in the computed tomography, and with the presence of acute neurological deterioration consisting at least of Glasgow Coma Scale (GCS) < 9 [15]. We excluded patients with malignant disease, comfort measures only, age less than 18 years, or inflammatory disease.

We collected sex, age, and the history of chronic obstructive pulmonary disease (COPD), diabetes mellitus, heart failure, chronic renal failure, and arterial hypertension. In addition, we registered body temperature, GCS, Acute Physiology and Chronic Health Evaluation II (APACHE II) score [16], bilirubin, sodium, lactic acid, creatinine, glycemia, fraction of inspired oxygen (FiO₂), partial pressure of arterial oxygen (PaO₂), platelets, leukocytes, fibrinogen, hemoglobin, international normalized ratio (INR), activated partial thromboplastin time (aPTT), hemorrhagic transformation, volume infarction, midline shift, and the realization of decompressive craniectomy.

Our end-point study was mortality at 30 days. In addition, we collected RDW and blood levels of tumor necrosis factor (TNF)-alpha and malondialdehyde at days 1, 4, and 8 of MMCAI.

2.2. Statistical Methods

We used frequencies (percentages) and medians (25th–75th percentiles) to report categorical and continuous variables. The Chi-square test and Wilcoxon–Mann–Whitney test were used to compare categorical and continuous variables between survivor and non-survivor patients at 30 days.
capacity by RDW at days 1, 4, and 8 of MMCAI for 30-day mortality prediction was determined by receiver operating characteristic (ROC) analyses; and we reported specificities and sensitivities for the cut-offs of RDW (using Youden J index) at days 1, 4, and 8. To test the association between RDW and 30-day mortality, controlling for GCS, lactic acid, and platelet count was carried out using a multiple logistic regression analysis with the enter method. To determine the existence of an association between continuous variables, we used the coefficient of Spearman’s rank correlation. The programs LogXact 4.1 (Cytel Co., Cambridge, MA, USA), SPSS 17.0 (SPSS Inc., Chicago, IL, USA), and NCSS 2000 (Kaysville, UT, USA) were used in the statistical analyses. A difference with p-value < 0.05 was considered statistically significant.

3. Results

We found that the 37 survivor patients in respect to the 37 non-survivor patients had higher GCS and lower lactic acid (Table 1). We found higher RDW at days 1 (p < 0.001), 4 (p < 0.001), and 8 (p = 0.02) in non-survivor than in survivor patients (Table 2). In addition, we found higher blood levels (p < 0.001) of TNF-alpha and malondialdehyde at days 1, 4, and 8 in non-survivor than in survivor patients (Table 2).

Table 1. Characteristics of 30-day surviving and non-surviving patients.

|                          | Survivors (n = 37) | Non-Survivors (n = 37) | p-Value |
|--------------------------|-------------------|------------------------|---------|
| Age (years): median (p 25–75) | 60 (47–68)        | 61 (53–70)            | 0.50    |
| Female: n (%)            | 14 (37.8)         | 14 (37.8)             | 0.99    |
| Heart failure: n (%)     | 1 (2.7)           | 1 (2.7)               | 0.99    |
| Diabetes mellitus: n (%) | 5 (13.5)          | 9 (24.3)              | 0.37    |
| COPD: n (%)              | 1 (2.7)           | 1 (2.7)               | 0.99    |
| Chronic renal failure: n (%) | 2 (5.4)         | 2 (5.4)               | 0.99    |
| Arterial hypertension: n (%) | 21 (56.8)        | 19 (51.4)             | 0.82    |
| GCS score: median (p 25–75) | 8 (6–8)          | 6 (3–7)               | 0.01    |
| APACHE-II score: median (p 25–75) | 20 (16–25)   | 22 (19–27)            | 0.07    |
| Lactic acid (mmol/L): median (p 25–75) | 1.20 (0.90–1.70) | 1.60 (1.01–2.88)     | 0.03    |
| Temperature (°C): median (p 25–75) | 36.4 (36.0–37.0) | 36.9 (36.0–37.2)     | 0.10    |
| Bilirubin (mg/dL): median (p 25–75) | 0.60 (0.42–0.80) | 0.65 (0.35–1.13)     | 0.85    |
| Glycemia (g/dL): median (p 25–75) | 127 (102–170)  | 136 (113–161)         | 0.50    |
| Creatinine (mg/dL): median (p 25–75) | 0.80 (0.65–1.10) | 1.00 (0.70–1.20)     | 0.21    |
| Sodium (mEq/L): median (p 25–75) | 139 (136–143)  | 140 (138–143)         | 0.50    |
| PaO2 (mmHg): median (p 25–75) | 144 (104–285)  | 115 (94–267)          | 0.40    |
| PaO2/FIO2 ratio: median (p 25–75) | 293 (204–366)  | 248 (188–320)        | 0.18    |
| INR: median (p 25–75) | 1.06 (1.00–1.20) | 1.15 (1.01–1.31)      | 0.05    |
| aPTT (seconds): median (p 25–75) | 28 (25–30)      | 27 (26–32)            | 0.99    |
| Platelets: median ×10³/mm³ (p 25–75) | 200 (170–267) | 173 (134–212)        | 0.02    |
| Fibrinogen (mg/dL): median (p 25–75) | 445 (415–526) | 419 (339–612)       | 0.90    |
| Leukocytes: median ×10⁹/mm³ (p 25–75) | 12.2 (9.5–17.0) | 13.8 (9.3–17.7)      | 0.40    |
| Hemoglobin (g/dL): median (p 25–75) | 12.2 (11.4–14.5) | 12.5 (11.0–14.8)    | 0.97    |
| Thrombolysis: n (%)      | 12 (32.4)         | 12 (32.4)             | 0.99    |
| Hemorrhagic transformation: n (%) | 8 (21.6)      | 8 (21.6)              | 0.99    |
| Volume infarction (ml): median (p25–75) | 181 (105–235) | 190 (65–288)        | 0.72    |
| Midline shift (mm): median (p 25–75) | 6.5 (2.8–11.2) | 10.0 (4.0–15.0)     | 0.41    |
| Decompressive craniectomy: n (%) | 9 (24.3)       | 7 (18.9)             | 0.78    |

p 25–75 = percentile 25th–75th; COPD = Chronic Obstructive Pulmonary Disease; GCS = Glasgow Coma Scale; APACHE II = Acute Physiology and Chronic Health Evaluation II; PaO2 = pressure of arterial oxygen/fraction inspired oxygen; FIO2 = pressure of arterial oxygen/fraction inspired oxygen; INR = international normalized ratio; aPTT = activated partial thromboplastin time.
Table 2. Red blood cell distribution width (RDW), malondialdehyde, tumor necrosis factor (TNF)-alpha at days 1, 4, and 8.

| Parameters                     | Survivors          | Non-Survivors       | p-Value  |
|--------------------------------|--------------------|---------------------|----------|
| **Day 1**                      | (n = 37)           | (n = 37)            |          |
| RDW: median % (percentile 25–75) | 12.7 (11.2–13.2)   | 13.9 (13.0–17.0)   | <0.001   |
| Malondialdehyde: median nmol/mL (percentile 25–75) | 1.76 (1.39–2.24)   | 2.99 (2.08–4.17)   | <0.001   |
| TNF-alpha median pg/mL (percentile 25–75) | 9.8 (9.2–11.3)     | 15.5 (13.2–16.7)   | <0.001   |
| **Day 4**                      | (n = 37)           | (n = 20)            |          |
| RDW: median % (percentile 25–75) | 12.0 (10.3–14.5)   | 15.1 (14.0–17.1)   | <0.001   |
| Malondialdehyde: median nmol/mL (percentile 25–75) | 1.64 (1.37–1.90)   | 2.95 (2.50–3.19)   | <0.001   |
| TNF-alpha median pg/mL (percentile 25–75) | 9.8 (9.1–10.9)     | 14.9 (13.3–16.2)   | <0.001   |
| **Day 8**                      | (n = 37)           | (n = 13)            |          |
| RDW: median % (percentile 25–75) | 11.5 (9.9–14.0)    | 14.9 (12.7–16.9)   | 0.02     |
| Malondialdehyde: median nmol/mL (percentile 25–75) | 1.46 (1.19–1.92)   | 2.71 (2.52–2.88)   | <0.001   |
| TNF-alpha: median pg/mL (percentile 25–75) | 9.3 (8.9–10.4)     | 14.8 (13.5–17.2)   | <0.001   |

RDW: Red blood cell distribution width; TNF: tumor necrosis factor.

The area under curve (95% confidence interval) for prediction of 30-day mortality by RDW at days 1, 4, and 8 of MMCAI were 0.80 (0.69–0.89; p < 0.001), 0.79 (0.66–0.89; p < 0.001), and 0.73 (0.58–0.84; p = 0.02) respectively (Figure 1). Table 3 showed specificities and sensitivities for the cut-offs of RDW at days 1, 4, and 8 of MMCAI.

Table 3. Thirty-day mortality prognostic capability of red blood cell distribution width (RDW) at days 1, 4, and 8 of malignant middle cerebral artery infarction.

| Day 1    | Day 4    | Day 8    |
|----------|----------|----------|
| Cut-off of RDW in % | >12.8 | >13.9 | >12.0|
| Specificity (95% confidence interval) | 54% (37%–71%) | 68% (50%–82%) | 54% (37%–71%) |
| Sensitivity (95% confidence interval) | 92% (78%–98%) | 85% (62%–97%) | 85% (55%–98%) |

Regression analyses showed an association between RDW (odds ratio = 1.695; 95% CI = 1.230–2.335; p = 0.001) and 30-day mortality, controlling for lactic acid, GCS, and platelet count (Table 4). We found a positive association between RDW and serum TNF-alpha levels at days 1 (rho = 0.54; p < 0.001), 4 (rho = 0.45; p < 0.001), and 8 (rho = 0.50; p < 0.001) of MMCAI. Additionally, we found a positive association between RDW and serum malondialdehyde concentrations at days 1 (rho = 0.46; p < 0.001), 4 (rho = 0.40; p = 0.002), and 8 (rho = 0.48; p < 0.001) of MMCAI.
Table 4. Multiple logistic regression analysis to predict 30-day mortality.

| Variable                                      | Odds Ratio | 95% Confidence Interval | p   |
|-----------------------------------------------|------------|-------------------------|-----|
| Platelet count (each 1000/mm³)                | 0.995      | 0.987–1.003             | 0.22|
| Lactic acid (mmol/L)                          | 1.148      | 0.642–2.053             | 0.64|
| Glasgow Coma Scale (points)                    | 0.661      | 0.480–0.910             | 0.01|
| RDW (%)                                        | 1.695      | 1.230–2.335             | 0.001|

RDW: red blood cell distribution width.

4. Discussion

Previously, in a recently published meta-analysis, it has been found that high baseline RDW is associated with increased mortality in ischemic stroke, over all long-term mortality (mortality at one year or more) [10]. However, there is not conclusive data on the role of RDW for early mortality prediction in ischemic stroke. A study by Duchnowski et al. observed 14 patients developing perioperative ischemic stroke, of which four patients died during the first 30 days, which showed it is difficult to establish 30-day mortality prediction by RDW in ischemic stroke [14]. Thus, that non-survivors showed higher RDW during the first week of MMCAI showed that RDW at any time during the first week of MMCAI could be used as biomarker of early mortality, and that there is an association between RDW and early mortality according to the regression analysis, are three interesting novelties of our study. We think that all new findings could help physicians in the estimation of early prognosis in those patients.

We found that non-survivor patients had higher RDW and lactic acid, and lower GCS and platelet count. However, only the RDW and GCS of them were associated with mortality in the regression analysis. We included only those four variables in the multiple logistic regression analysis, due to the fact that we registered 37 deaths in our series, and those variables showed the highest differences between non-survivor and survivor patients. We have not included serum levels of TNF-alpha and malondialdehyde in the regression analysis due to the fact that we found an association between RDW, TNF-alpha, and malondialdehyde.

Different factors have been associated with the outcome stroke such as oxidation [17,18], inflammation [19–22], hyperglycemia [23], or alterations in brain perfusion due to blood pressure variability [24,25]. In addition, there has been found the association of RDW with oxidative stress in animal models [26], with blood TNF-alpha levels in critically ill patients [27,28], and with atrial fibrillation and its risk of complications and mortality [29–31]. Another novel finding of our study was that there is a positive association between RDW and blood levels of malondialdehyde and TNF-alpha during the first week of MMCAI. In summary, we found that non-survivor patients showed higher RDW, higher blood malondialdehyde levels, and higher blood TNF-alpha levels during the first week of TBI, and that those parameters are associated. We think that the association between mortality and RDW in MMCAI patients could be due to a higher oxidative state and a higher inflammation state.

Some limitations of our study was that data on folate, iron, vitamin B12, blood smear, and reticulocyte count to complete the description of red blood cell has been not reported. In addition, we have not registered some factors that could be associated with outcome stroke and RDW as atrial fibrillation and blood pressure variability. However, we think that our study has some strengths, as we reported data on RDW, malondialdehyde levels, and TNF-alpha levels during the first week of MMCAI.

We believe that there are multiple factors associated with outcome stroke, many of them are easily obtainable (blood biomarkers of inflammatory and oxidation) and may be incorporated into clinical scoring systems to improve outcome prediction. In addition, many of those factors are modifiable and can become targets of therapeutic interventions. In this respect, we believe that the use of RDW could
be standardized for early mortality prediction in MMCAI due to the fact that RDW is a laboratory parameter that is automatically in conventional hemograms.

5. Conclusions

The association between RDW and early mortality, and the potential role of RDW during the first week of MMCAI as a prognostic biomarker of early mortality were the main novelties of our study.

Author Contributions: L.L. conceived, designed and coordinated the study, participated in acquisition and interpretation of data, and drafted the manuscript; M.M.M., L.R.-G., M.A., J.S.-V., J.J.C., and V.G.-M. participated in acquisition of data; P.A.-G., A.P.-C., and A.F.G.-R. participated in blood determination levels; A.J. participated in the interpretation of data. All authors revised the manuscript critically for important intellectual content. All authors have read and agreed to the published version of the manuscript.

Funding: This study was supported by a grant (OA18/011) from Fundación DISA a la Investigación Médica 2017 (Santa Cruz de Tenerife, Spain), a grant from Instituto de Salud Carlos III (PI-18-00500) (Madrid, Spain), and co-financed with Fondo Europeo de Desarrollo Regional (FEDER).

Conflicts of Interest: The authors declare no conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

References

1. Aslan, D.; Gümrük, F.; Gürgey, A.; Altay, C. Importance of RDW value in differential diagnosis of hypochromic anemias. Am. J. Hematol. 2002, 69, 31–33. [CrossRef] [PubMed]
2. Abrahan, L.L., 4th; Ramos, J.D.A.; Cunanan, E.L.; Tiongson, M.D.A.; Punzalan, F.E.R. Red Cell Distribution Width and Mortality in Patients with Acute Coronary Syndrome: A Meta-Analysis on Prognosis. Cardiol. Res. 2018, 9, 144–152. [CrossRef] [PubMed]
3. Fontana, V.; Spadaro, S.; Villois, P.; Higby Shinotsuka, C.; Fogagnolo, A.; Nobile, L.; Vincent, J.L.; Creteur, J.; Taccone, F.S. Can red blood cell distribution width predict outcome after cardiac arrest? Minerva Anestesiol. 2018, 84, 693–702.
4. Salvatori, M.; Formiga, F.; Moreno-Gonzalez, R.; Chivite, D.; Migone De Amicis, M.; Cappellini, M.D.; Corbella, X. Red blood cell distribution width as a prognostic factor of mortality in elderly patients firstly hospitalized due to heart failure. Kardiol. Pol. 2019, 77, 632–638. [CrossRef] [PubMed]
5. Goyal, H.; Awad, H.; Hu, Z.D. Prognostic value of admission red blood cell distribution width in acute pancreatitis: A systematic review. Ann. Transl. Med. 2017, 5, 342. [CrossRef]
6. Milas, G.P.; Karageorgiou, V.; Cholongitas, E. Red cell distribution width to platelet ratio for liver fibrosis: A systematic review and meta-analysis of diagnostic accuracy. Expert Rev. Gastroenterol. Hepatol. 2019, 13, 877–891. [CrossRef]
7. Hu, Z.D.; Lippi, G.; Montagnana, M. Diagnostic and prognostic value of red blood cell distribution width in sepsis: A narrative review. Clin. Biochem. 2020, 77, 1–6. [CrossRef]
8. Lorente, L.; Martín, M.M.; Abreu-González, P.; Solé-Violán, J.; Ferreres, J.; Labarta, L.; Díaz, C.; González, O.; García, D.; Jiménez, A.; et al. Red Blood Cell Distribution Width during the First Week Is Associated with Severity and Mortality in Septic Patients. PLoS ONE 2014, 9, e105436. [CrossRef]
9. Zhang, B.; Zhao, J. Red blood cell distribution width as a prognostic biomarker for mortality in traumatic brain injury. Int. J. Clin. Exp. Med. 2015, 8, 19172–19175.
10. Song, S.Y.; Hua, C.; Dornbors, D., 3rd; Kang, R.J.; Zhao, X.X.; Du, X.; He, W.; Ding, Y.C.; Meng, R. Baseline Red Blood Cell Distribution Width as a Predictor of Stroke Occurrence and Outcome: A Comprehensive Meta-Analysis of 31 Studies. Front. Neurol. 2019, 10, 1237. [CrossRef]
11. Wang, F.; Yu, Q.; Wu, X.; Ju, X.; Wang, L.; Hu, S. Correlation between the red blood cell distribution width and prognosis in elderly patients with cerebral infarction and severe hemiplegia. Chin. J. Cerebrovasc. Dis. 2015, 6, 287–291.
12. Fan, L.; Gó, L.; Chai, E.Q.; Wei, C.J. Routine hematological parameters are associated with short- and long-term prognosis of patients with ischemic stroke. J. Clin. Lab. Anal. 2018, 32, 2. [CrossRef] [PubMed]
13. Kim, J.; Kim, Y.D.; Song, T.J.; Park, J.H.; Lee, H.S.; Nam, C.M.; Nam, H.S.; Heo, J.H. Red blood cell distribution width is associated with poor clinical outcome in acute cerebral infarction. *Thromb. Haemost.* 2012, 108, 349–356. [CrossRef] [PubMed]

14. Duchnowski, P.; Hryniewiecki, T.; Kusmierzcyk, M.; Szymanski, P. Red cell distribution width is a prognostic marker of perioperative stroke in patients undergoing cardiac valve surgery. *Interact. Cardiovasc. Thorac. Surg.* 2017, 25, 925–929. [CrossRef] [PubMed]

15. Teasdale, G.; Jennett, B. Assessment of coma and impaired consciousness. A practical scale. *Lancet* 1974, 2, 81–84. [CrossRef]

16. Knaus, W.A.; Draper, E.A.; Wagner, D.P.; Zimmerman, J.E. APACHE II: A severity of disease classification system. *Crit. Care Med.* 1985, 13, 818–829. [CrossRef]

17. Lorente, L.; Martín, M.M.; Abreu-González, P.; Ramos, L.; Argueso, M.; Solé-Violán, J.; Riaño-Ruiz, M.; Jiménez, A. Serum malondialdehyde levels in patients with malignant middle cerebral artery infarction are associated with mortality. *PLoS ONE* 2015, 10, e0125893. [CrossRef]

18. Lorente, L.; Martín, M.M.; Abreu-González, P.; Sabatel, R.; Ramos, L.; Argueso, M.; Solé-Violán, J.; Riaño-Ruiz, M.; García-Marin, V. Serum malondialdehyde levels and mortality in patients with spontaneous intracerebral haemorrhage. *World Neurosurg.* 2018, 113, e542–e547. [CrossRef]

19. Zangari, R.; Zanier, E.R.; Torgano, G.; Beretta, S.; Beghi, E.; Casolla, B.; Checcharelli, N.; Lanfranconi, S.; Maino, A.; et al. Early ficolin-1 is a sensitive prognostic marker for functional outcome in ischemic stroke. *J. Neuroinflammation* 2016, 13, 16. [CrossRef]

20. Di Napoli, M.; Slevin, M.; Popa-Wagner, A.; Singh, P.; Lattanzi, S.; Divani, A.A. Monomeric C-Reactive Protein and Cerebral Hemorrhage: From Bench to Bedside. *Front. Immunol.* 2018, 9, 1921. [CrossRef]

21. Lattanzi, S.; Di Napoli, M.; Ricci, S.; Divani, A.A. Matrix Metalloproteinases in Acute Intracerebral Hemorrhage. *Neurotherapeutics* 2020. [CrossRef] [PubMed]

22. Winters, O.; O’Connor, J.J. A role for tumor necrosis factor-α in ischemia and ischemic preconditioning. *J. Neuroinflammation* 2011, 8, 87. [CrossRef] [PubMed]

23. Kagansky, N.; Levy, S.; Knobler, H. The Role of Hyperglycemia in Acute Stroke. *Arch. Neurol.* 2001, 58, 1209–1212. [CrossRef] [PubMed]

24. Geng, X.; Liu, X.; Li, F.; Wang, J.; Sun, H.; Feng, A.; Sun, Y.; Sun, H.; Yang, F.; Zhao, J.; et al. Blood Pressure Variability at Different Time Periods Within First 24 Hours After Admission and Outcomes of Acute Ischemic Stroke. *J. Clin. Hypertens.* 2020, 22, 194–204. [CrossRef] [PubMed]

25. Divani, A.A.; Liu, X.; Di Napoli, M.; Lattanzi, S.; Ziai, W.; James, M.L.; Jafarli, A.; Jafari, M.; Saver, J.L.; Hemphill, J.C.; et al. Blood Pressure Variability Predicts Poor In-Hospital Outcome in Spontaneous Intracerebral Hemorrhage. *Stroke* 2019, 50, 2023–2029. [CrossRef]

26. Ghaifari, S. Oxidative stress in the regulation of normal and neoplastic hematopoiesis. *Antioxid. Redox Signal.* 2008, 10, 1923–1940. [CrossRef]

27. Scharte, M.; Fink, M.P. Red blood cell physiology in critical illness. *Crit. Care Med.* 2003, 31, S651–S657. [CrossRef]

28. Pierce, C.N.; Larson, D.F. Inflammatory cytokine inhibition of erythropoiesis in patients implanted with a mechanical circulatory assist device. *Perfusion* 2005, 20, 83–90. [CrossRef]

29. Lippi, G.; Cervellin, G.; Sanchis-Gomar, F. Red blood cell distribution width: A marker of anisocytosis potentially associated with atrial fibrillation. *World J. Cardiol.* 2019, 11, 292–304. [CrossRef]

30. Weymann, A.; Ali-Hasan-Al-Saegh, S.; Sabashnikov, A.; Popov, A.F.; Mirhosseini, S.J.; Liu, T.; Lotfaliani, M.; Sá, M.P.B.O.; Baker, W.L.L.; Yavuz, S.; et al. Prediction of New-Onset and Recurrent Atrial Fibrillation by Complete Blood Count Tests: A Comprehensive Systematic Review with Meta-Analysis. *Med. Sci. Monit. Basic Res.* 2017, 23, 79–222. [CrossRef]

31. Weymann, A.; Ali-Hasan-Al-Saegh, S.; Popov, A.F.; Sabashnikov, A.; Mirhosseini, S.J.; Liu, T.; Tse, G.; Lotfaliani, M.; Ghanei, A.; Testa, L.; et al. Haematological indices as predictors of atrial fibrillation following isolated coronary artery bypass grafting, valvular surgery, or combined procedures: A systematic review with meta-analysis. *Kardiol. Pol.* 2018, 76, 107–118. [CrossRef] [PubMed]